| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
Published online before print April 27, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
@,
,,,
*Division of Infectious Diseases and Department of Pathology, Harbor-University of California at Los Angeles Medical Center; and The David Geffen School of Medicine at the University of California at Los Angeles
@ To whom correspondence should be addressed. E-mail: bspellberg{at}labiomed.org.
 |
Abstract |
|---|
Disseminated candidiasis is a frequent infection in neutropenic patients, in whom it causes 50% mortality, despite antifungal therapy. As the duration of neutropenia is the strongest predictor of survival in neutropenic patients with invasive fungal infections, neutrophil transfusions are a logical, therapeutic option. However, significant technical barriers have prevented the clinical use of neutrophil transfusions. To overcome these barriers, we identified a human phagocytic cell line that could be administered to candidemic hosts in lieu of freshly harvested neutrophils. HL-60 cells killed Candida albicans in vitro. Activation of HL-60 cells with dimethyl sulfoxide and retinoic acid abrogated cells’ proliferation and augmented their killing of C. albicans. Administration of activated HL-60 cells to candidemic, neutropenic mice significantly improved survival (53% vs. 0%). Live HL-60 cells chemotaxed to sites of infection, phagocytized C. albicans, and reduced the fungal burden in key target organs. Although unactivated HL-60 cells also reduced tissue fungal burden in vivo, they did not improve survival as a result of their toxicity in infected mice. In contrast, no toxicity as a result of activated HL-60 cells was observed at up to 2 months of follow-up. To our knowledge, this is the first description of a cell line-based immunotherapy for an infectious disease. With further refinements, activated HL-60 cells have the potential to overcome the technical barriers to neutrophil transfusions.
Key Words: HL-60 • immunotherapy • Candida albicans • white cell transfusions
This article has been cited by other articles:
|
|
 |
|
  Y. Fu, G. Luo, B. J. Spellberg, J. E. Edwards Jr., and A. S. Ibrahim Gene Overexpression/Suppression Analysis of Candidate Virulence Factors of Candida albicans Eukaryot. Cell, March 1, 2008; 7(3): 483 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Spellberg, M. Collins, V. Avanesian, M. Gomez, J. E. Edwards Jr., C. Cogle, D. Applebaum, Y. Fu, and A. S. Ibrahim Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts J. Leukoc. Biol., March 1, 2007; 81(3): 632 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Hope, G. L. Drusano, C. B. Moore, A. Sharp, A. Louie, T. J. Walsh, D. W. Denning, and P. A. Warn Effect of Neutropenia and Treatment Delay on the Response to Antifungal Agents in Experimental Disseminated Candidiasis Antimicrob. Agents Chemother., January 1, 2007; 51(1): 285 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Spellberg, J. Schwartz, Y. Fu, V. Avanesian, J. Adler-Moore, J. E. Edwards Jr, and A. S. Ibrahim Comparison of antifungal treatments for murine fusariosis J. Antimicrob. Chemother., November 1, 2006; 58(5): 973 - 979. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
